- Current opinion in investigational drugs
-
影响因子:
3.553
-
I S S N:
1472-4472
-
出 版 社:
Thomson Reuters (Scientific) Ltd
-
出 版 地:
London
-
出版国家:
England
-
刊 期:
月刊
-
创刊时间:
2000
-
语 种:
英文
-
审稿周期:
12周,或约稿
-
中科院分区:
3
-
投稿命中率:
一般
-
国外数据库收录:
IM
-
中国收录文章数:
1
-
5年影响因子:
3.006
-
研究领域:
抗感染药物、抗炎剂、抗肿瘤药、心血管药物、中枢神经系统药物、临床试验专题、药物研究
-
官方链接:
http://www.biomedcentral.com/about
-
投稿须知:
http://www.biomedcentral.com/about
期刊介绍:
Current Opinion in Investigational Drugs is a monthly publication covering all therapeutic areas, in recognition of the increasingly multi-disciplinary nature of modern drug discovery and development. With Current Opinion in Investigational Drugs, we aim to help the reader by providing in a systematic manne critical reviews of selected areas of investigational drug research, expert evaluation of selected drugs currently in clinical trials, selection of the most interesting papers and patents, annotated by experts. Six therapeutic categories are covered with each being featured in separate journal issues, and each therapeutic area being covered twice-yearly. The broad therapeutic categories and the specialist topics within each are as follows: Anti-infectives Antifungals and antiparasitics; antibacterials (b-lactams, glycopeptides and other agents); antibacterials (quinolones, macrolides and oxazolidinones); vaccines; antivirals (HIV); antivirals (non-HIV); Anti-inflammatory, Immunologicals and Biologicals Musculoskeletal; respiratory; dermatology; nervous system; transplantation; Cardiovascular and Renal Hypertension and renal failure; stroke and angina; arrhythmia and heart failure; antithrombotics; hemostasis and hematological diseases; atherosclerosis, hypercholesterolemia and heart disease; Endocrine and and Metabolics Diabetes, reproductive endocrinology, hormone disorders, bone metabolism and obesity; Central and Peripheral Nervous System Pain; neuro-urology and neurogastroenterology; neurodegenerative and cognitive disorders; affective/behavioral/personality disorders and substance abuse; neurology and neuroprotection; schizophrenia and psychosis; Oncological Cell signaling modulators; cytotoxic drugs; immunotherapeutic drugs and monoclonal antibodies; protein therapeutics, including growth factors; gene therapy; antisense inhibitors